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The cumulative duration of depressive episodes, and their repetition, has a detrimental effect on
depression recurrence rates and the chances of antidepressant response, and even increases the risk
of dementia, raising the possibility that depressive episodes could be neurotoxic. Psychomotor
retardation could constitute a marker of this negative burden of past depressive episodes, with
conﬂicting ﬁndings according to the use of clinical versus cognitive assessments. We assessed the role
of the Retardation Depressive Scale (ﬁlled in by the clinician) and the time required to perform the
neurocognitive d2 attention test and the Trail Making Test (performed by patients) in a sample of
2048 depressed outpatients, before and after 6 to 8 weeks of treatment with agomelatine. From this
sample, 1140 patients performed the TMT-A and -B, and 508 performed the d2 test, at baseline and
after treatment. At baseline, we found that with more past depressive episodes patients had more
severe clinical level of psychomotor retardation, and that they needed more time to perform both d2
and TMT. When the analyses were performed again after treatment, and especially when the analyses
were restricted to patients with clinical remission, the cognitive tests were the only ones correlated
with past depressive episodes. Psychomotor retardation tested at a cognitive level was therefore
systematically revealing the burden of past depressive episodes, with an increased weight for
patients with less remaining symptoms. If prospectively conﬁrmed, interventions such as cognitive
remediation therapy could beneﬁt from a more speciﬁc focus on neurocognitive retardation.
& 2014 Elsevier B.V. and ECNP. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/)..013
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The cumulative duration of depressive episodes, as well as
their repetition, has a detrimental effect on depression
recurrence rates (Solomon et al., 1997), the chances of
antidepressant response (Keller et al., 1992), time to obtain
remission (Kanai et al., 2003), and the presence of social
recovery (Sarapas et al., 2013). Memory impairment (Burt
et al., 1995), atrophy of the hippocampus (Sheline et al.,
1999), and higher risk for dementia (Kessing, 2012) have
also been observed, raising the possibility that depressive
episodes could be neurotoxic (Gorwood et al., 2008).
Some neurocognitive deﬁcits may constitute a core
feature of major depressive disorder (MDD), as they have
also been observed during clinical remission (Austin et al.,
2001; Bhardwaj et al., 2010; Weiland-Fiedler et al., 2004)
and predict a higher degree of follow-up symptoms over and
above the initial symptoms (Sumner et al., 2010). The
cognitive functions involved concern reduced memory capa-
city (Gorwood et al., 2008), decreased ﬂexibility and
psychomotor speed (Beats et al., 1996; Austin et al.,
2001), attention and set-shifting deﬁcits (Purcell et al.,
1997; Austin et al., 2001), reduced vigilance, and psycho-
motor slowness (Den Hartog et al., 2003; Egeland et al.,
2003; Arnett et al., 1994; Kertzman et al., 2010). The fact
that Attention Deﬁcit-Hyperactivity Disorder symptom
severity was signiﬁcantly correlated with the occurrence
of lifetime depressive episodes, even after controlling for
current comorbidity (Simon et al., 2013), might also plead
in favor of a tight relationship between attention processes
and major depressive disorder.
Psychomotor retardation could be involved more speciﬁ-
cally. Not only is this considered a core clinical feature of
depression by many clinicians (Widlocher, 1983), but it is
also a neurocognitive trait frequently assessed in mood
disorders. For example, the presence of ‘marked psycho-
motor retardation’ is included among the symptom criteria
required for a diagnosis of a depressive episode in the ﬁfth
edition of the Diagnostic and Statistical Manual of Mental
Disorders (DSM-5) and has proven to have both diagnostic
and prognostic value in major depression (Calugi et al.,
2011). Psychomotor retardation can also be easily assessed
as a cognitive trait through the use of simple drawing tasks
(Sabbe et al., 1999; Buyukdura et al., 2011), which have the
advantage of being independent from clinical assessments,
the latter being frequently contaminated by the severity of
depressive symptoms. High levels of psychomotor retarda-
tion have indeed been observed in depressed patients using
a variety of paradigms, even in patients who are in
remission (Beats et al., 1996; Austin et al., 2001; Den
Hartog et al., 2003; Egeland et al., 2003; Arnett et al.,
1994; Kertzman et al., 2010; Hasselbalch et al., 2013).
The link between psychomotor retardation in depressive
disorder and cognitive impairment remaining after depres-
sive disorder needs to be highlighted because of the
therapeutic strategies that could be involved. Actually,
clinical psychomotor retardation, unlike the intensity of a
depressive episode, appears to correlate with a decrease in
performance level on attentive tasks, which attests to the
speciﬁc value of clinical psychomotor retardation as a
predictor of cognitive deﬁcits in depressed patients
(Lemelin and Baruch, 1998). Furthermore, in a study inpatients with remitted MDD, the deﬁcit in psychomotor
speed remained signiﬁcant, suggesting that it constitutes a
vulnerability marker for, or stigma of, MDD (Weiland-Fiedler
et al., 2004).
Two tests are of signiﬁcant interest when assessing
psychomotor retardation as well as attentive and set-
shifting processes. One of these is a Trail Making Test (TMT
A & B), a frequently-used neurocognitive drawing test that
can measure psychomotor retardation (Buyukdura et al.,
2011; Partington, 1949), especially when the interest is in
speed rather than number of mistakes. The other is the d2
test of attention, a graphic-motor test of cancellation
aimed at assessing basic attention level (Brickenkamp,
1981) through the number of correct items quoted by the
patient within a limited amount of time. As the three tests
(d2 test, TMT-A, and TMT-B) all rely on speed, they are good
indicators of psychomotor retardation. However, these tests
vary in terms of their level of demand and thus have
variable sensitivity for psychomotor retardation: the d2 test
(theoretically) is limited to the attention process, while
TMT-A also involves a motor task (drawing adequate lines)
and TMT-B, besides these aspects, also requires set-shifting
skills.
The majority of studies, but not all, report beneﬁcial
effects of antidepressants in improving different neurocog-
nitive functions (i.e., executive function, memory, and/or
attention skills) in depressed patients (for example Herrera-
Guzman et al., 2009), including psychomotor retardation.
We focused on agomelatine because of its activity in
relation to circadian rhythms, which are an important
aspect of psychomotor retardation (Moffoot et al., 1994;
Sabbe et al., 1999). The other reason for our focus on
agomelatine was its activity in relation to dopamine neuro-
transmission (Chenu et al., 2013), a key player in psycho-
motor retardation (Rampello et al., 1991).
In order to more precisely deﬁne which stigmas charac-
terize patients with past depressive episodes, we analyzed
the level of psychomotor retardation in depressed patients
and tested the hypothesis that it would reﬂect the number
of past depressive episodes, even when patients are in
clinical remission. Furthermore, we also tested whether a
simple cognitive drawing test (TMTand/or d2 tests) could be
more informative in determining past depressive episodes
than a speciﬁc scale assessing clinical psychomotor retarda-
tion (the retardation depressive scale [RDS]). To test this
hypothesis, we analyzed different aspects of psychomotor
retardation using data from an original, large, prospective
and non-interventional study of agomelatine in the treat-
ment of depressed outpatients, which included neurocogni-
tive tests in a subsample of patients assessed before and
after treatment.2. Experimental procedures
The present multicentre, non-interventional study was conducted
in a naturalistic treatment setting in 388 community psychiatry
centres in France between October 2011 and October 2012. A total
of 2048 outpatients (Table 1) were initially recruited, all of whom
fulﬁlled the DSM-IV criteria for major depressive disorder and
required (according to the clinician) the prescription of one (and
only one) antidepressant treatment. Exclusion criteria were being
aged under 18 years, having a psychotic manifestation, an
Table 1 Demographic and clinical characteristics of 2048 depressed outpatients at baseline.
Characteristics Subgroups Baseline values
N % Average SD
Gender Female 1290 63.14
Male 753 36.86
Age (years) 45.38 12.27
Marital status Single, divorced, or widowed 1061 53.08
Married/partner 938 46.92
Highest educational level Below high school 1094 55.62
High school and over 873 44.38
Professional activity Presently working 811 43.37
Retired, unemployed, disability, or sick leave 1059 56.63
Length of present episode (weeks) 9.90 25.98
Number of past episodes 0.91 1.66
0 (ﬁrst episode) 1207 61.64
1 276 14.10
2 203 10.37
3 128 6.54
4 and more 144 7.35
SD; standard deviation.
P. Gorwood et al.1632associated axis I psychiatric illness, a severe or unstable medical
condition (i.e., hepatic insufﬁciency), a current diagnosis of sub-
stance abuse (drug or alcohol), pregnancy or lactation, antipsycho-
tic and benzodiazepine treatment, and administration of
electroconvulsive therapy in the preceding 6 months. Patients were
assessed twice – once at baseline (before treatment) and once after
6 to 8 weeks of medication. The average delay before this second
visit was 50 days (standard deviation [SD]=11 days). As we did not
ﬁnd any impact of this delay on the clinical and cognitive
characteristics of patients at the second visit, this parameter was
not controlled for.
The study was approved by the French National Ethics Commit-
tee and all patients gave written informed consent prior to
participation. All data were recorded anonymously.2.1. Clinical assessments
A number of socio-demographic characteristics were assessed
(Table 1), and these were simpliﬁed in the statistical analyses to
focus on the most informative aspects. Accordingly, the level of
education was analyzed as being below or above high school level,
marital status as living or not with a partner, and professional
activity as being presently active or not (Table 1).
The diagnostic of major depressive episode was based on
(1) clinician diagnosis (as the decision to ‘prescribe an antidepres-
sant to treat a major depressive episode’ was the inclusion
criteria), (2) a speciﬁc assessment of the nine DSM-IV criteria for
major depressive episode (and the fact that at least 5 of these
criteria are present) and the (3) Self-Report Quick Inventory of
Depressive Symptomatology (QIDS-SR). This 16-item brief rating of
depressive symptoms was designed to assess severity, but has highly
acceptable psychometric properties and usefulness (Rush et al.,
2003) and good capacity to correctly classify depressed patients in
primary care centres (Lamoureux et al., 2010).
The threshold for clinical remission was deﬁned as a QIDS-SR
score of r5 (Rush et al., 2003).
The Widlöcher RDS is a 15-item scale ﬁlled in by a clinician. It
assesses cognitive and motor aspects of psychomotor retardation
(Widlocher, 1983).The Sheehan Disability Scale (SDS) is a brief self-report tool that
assesses functional impairment in three related domains: work/
school, social, and family life. The patients rate the extent to which
their responsibilities in each domain are impaired by their symp-
toms on a 10-point visual analog scale (Leon et al., 1992).2.2. Cognitive tasks
The d2 test was completed ﬁrst, followed by TMT-A and TMT-B. The
d2 test of attention is a graphic-motor test of cancellation aimed at
assessing attention (Brickenkamp, 1981). The test includes a task
involving the cancellation of speciﬁc designated letters (p or d) with
small vertical lines above and/or below the letters. The test has 14
rows of 47 characters in each row – a total of 658 characters.
Participants are allowed 20 s to cancel the designated letter (the
letter d) on each row, with 2 small vertical lines below and/or
above the letter. The task lasts for 4 min and 40 s. Before starting
the test in our study, each participant was given a full explanation
and practiced the task in a one-line trial. The test assessed
attention through the rate of cancellation, accuracy, consistency
of the work, and the number of mistakes. Generated variables
mainly include total signs marked (GZ, quantitative performance
index), total signs correctly marked (BR), and total signs correctly
marked minus incorrect marked items (KL, concentration perfor-
mance index). Qualities of the test include a test–retest reliability
of 40.90 in numerous studies (Antretter et al., 2013).
The TMT (Partington, 1949) is a commonly-used neuropsycholo-
gical drawing test that can measure psychomotor retardation
(Buyukdura et al., 2011). The TMT consists of two parts: TMT-A
requires the drawing of lines sequentially to connect 25 encircled
numbers distributed on a sheet of paper in ascending order. Task
requirements are similar for TMT-B, except that the subject must
alternate between numbers and letters (1, A, 2, B, 3, C, and so on).
The score for each part represents the amount of time required to
complete the task. It was originally designed to test processing
speed (TMT-A) or cognitive and attentive ﬂexibility (TMT-B)
(Misdraji and Gass, 2010), but it also provides information on visual
search, sequencing, and conceptual tracking (Mahurin et al., 2006).
For the TMT, the examiner was instructed to monitor the ongoing
progress of the test and to intervene to correct mistakes at the time
Table 2 Clinical and cognitive characteristics of 2048 depressed outpatients at baseline and 6 to 8 weeks after treatment.
Baseline values Follow-up values Statistics
N Average SD Average SD t df p
QIDS-SR total score 2048 16.10 4.47 7.12 4.95% 60.95 4094 o103
CGI-S score 2048 4.76 0.76 2.22 0.96 92.82 4094 o103
RDS score 2002 26.55 8.78 11.37 8.46 55.71 4002 o103
SDS score 2002 20.25 5.24 10.16 6.71 53.02 4002 o103
Work/studies 6.67 1.95 3.31 2.54 46.95 4002 o103
Social life 6.91 1.92 3.56 2.68 45.47 4002 o103
Family 6.56 1.99 3.29 2.65 44.15 4002 o103
TMT-A neurocognitive test 1140
Time (seconds) 63.18 58.44 40.38 36.82 11.14 2278 o103
Mistakes (number) 0.72 1.57 0.43 3.24 2.72 2278 o103
TMT-B neurocognitive test 1140
Time (seconds) 96.88 77.31 66.37 58.77 17.52 2278 o103
Mistakes (number) 2.16 5.90 1.06 4.79 4.89 2278 o103
d2 neurocognitive test 508
GZ (number of marked items) 318.09 173.64 381.07 167.44 5.88 1014 o103
BR (number of correct marked items) 114.60 72.27 140.91 69.48 5.92 1014 o103
Kl (correct marked items–incorrect marked items) 105.68 72.67 132.81 71.28 6.01 1014 o103
CGI-S, Clinical Global Impression Severity; QIDS-SR, Self-Report Quick Inventory of Depressive Symptomatology; RDS, Retardation
Depressive Scale; SDS, Sheehan Disability Scale; TMT, Trail Making Test.
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of the test was not stopped during this intervention, time for
correction of errors is included in the total time for completion of
the test.
TMT-A and TMT-B (N=1080) and d2 (N=508) were performed and
informative for only one quarter of the sample (24.80%). These
patients were comparable to the rest of the sample regarding age
(p=0.128), gender (p=0.406), marital status (p=0.869), profes-
sional status (p=0.678), number of past depressive episodes
(p=0.345), baseline (p=0.111) and post-treatment (p=0.408)
values of depression severity, RDS psychomotor retardation level
(p=0.273), and post-treatment values of RDS psychomotor retarda-
tion (p=0.248). Patients who performed the neurocognitive tests
nevertheless had a tendency for more frequent rates of remission
(44.91% vs 41.53%, p=0.062).
The existence of a practice effect was indirectly assessed in the
subgroup of patients with identical QIDS-SR global scores at both visits.
In this subgroup of 14 patients, the difference in the values between the
two visits did not reach the signiﬁcance level (TMT-A time
[mean=0.615 s; SD=16.993; p=0.898], TMT-B time [mean
=5.182 s; SD=29.630; p=0.585], and the GZ [mean =+14.667 signs,
SD=140.025, p=0.775]), BR [mean =+6.222 signs; SD=73.578;
p=0.806] and KL [mean =+4.556 signs, SD=57.133, p=0.844] indexes
of the d2 test).2.3. Treatment, follow-up, and data collection
All patients received agomelatine (25–50 mg) once daily at bedtime.
Patients were evaluated at the inclusion visit, when their eligibility
criteria were veriﬁed, data on demographic, clinical, and cognitive
variables at baseline documented, and treatment with agomelatine
25 mg initiated. Patients then returned for one follow-up visit
between week 6 and week 8, when clinical response was evaluated
with a severity rating scale completed by the physician (Clinical
Global Impression-Severity [CGI-S] scale) and patient (QIDS-SR), and
cognitive tests were again performed.2.4. Statistical analyses
A graphical appreciation was used to assess the normality of distribution
of the factors analyzed (at baseline and the second visit). Q–Q plots were
thus performed and showed that dependent variables were close enough
to the normal distribution.
A Student's t-test was used to determine the difference between
continuous variables and Chi-square test in order to compare binary
variables. As age, educational level, and professional activity were
signiﬁcantly involved in either the number of past depressive
episodes or in cognitive tests (Tables 3 and 4), these items were
controlled for when needed (and indicated) as co-variables in
quantitative analyses; i.e., partial correlation or analyses of
covariance was used controlling for these three factors.
All statistical analyses were carried out using an SPSS 15.0 (IBM,
Armonk, NY, USA).3. Results
3.1. Baseline values of the sample
At inclusion, the majority of the sample was female and on
an average 45 years old, with approximately half being
married or living with a partner and presently working
(Table 1). It was the ﬁrst episode for 6 out of 10 patients,
but for 13.9% it was the third episode or more (Table 1). The
baseline severity on the QIDS-SR was around 16, which was
in accordance with the clinicians' rating (the CGI-S being
quoted as 5 or above [markedly ill] for 70.3% of patients)
(Table 2). The average psychomotor retardation (according
to the RDS) was 27 (the worst value being 60), and the
average social functioning level (assessed by the SDS) was
20 (the worst value being 30). For the neurocognitive tests
at baseline, 1 min was required on an average to perform
the TMT-A at baseline, with on average only one mistake
Table 3 Clinical and socio-demographic characteristics of patients with baseline psychomotor retardation below or over the
media value (27) of the RDS.
Baseline psychomotor retardation level Statistics
Lowest values
(N=1025)
Highest values
(N=1023)
Characteristics N Average SD N Average SD t c2 df p
Gender Female 610 635
Male 339 387 0.97 1 0.324
Marital status Single, divorced, or widowed 508 451
Married/partner 419 481 7.65 1 0.006
Highest
educational level
Below high school 467 595
High school and over 439 400 13.10 1 o0.001
Professional
activity
Presently working 417 362
Retired, unemployed, disability,
or sick leave
450 582 17.52 1 o0.001
QIDS-SR 13.87 4.10 18.17 3.66 24.47 1972 o0.001
CGI-S 4.42 0.74 5.14 0.57 24.30 1972 o0.001
SDS 17.96 5.42 21.96 4.08 15.07 1314 o0.001
d2 tests GZ 354.52 166.92 282.93 171.21 4.70 491 o0.001
BR 128.31 70.12 101.14 70.78 4.28 491 o0.001
KL 120.04 72.13 91.44 69.44 4.47 491 o0.001
TMT TMT-A (time) 55.31 44.79 70.53 67.78 4.18 967 o0.001
TMT-A (mistakes) 0.59 1.50 0.83 1.62 2.44 1060 0.007
TMT-B (time) 87.97 67.33 105.14 84.94 3.38 898 o0.001
TMT-B (mistakes) 1.72 4.18 2.49 7.05 2.09 936 0.018
CGI-S, Clinical Global Impression Severity; QIDS-SR, Self-Report Quick Inventory of Depressive Symptomatology; RDS, Retardation
Depressive Scale; SDS, Sheehan Disability Scale; TMT, Trail Making Test.
P. Gorwood et al.1634recorded, while 50% more time was needed for the TMT-B
test to be performed, with two mistakes recorded on an
average. The results of the d2 test (GZ, BR, and Kl scores)
are detailed in Table 2. As expected, the RDS total score
correlated highly with all aspects of the d2 and with the
speed characteristics of the TMT tests (po0.003), even
when controlling for educational level, professional activity,
and age (po0.004). Patients with higher (versus lower)
clinical level of psychomotor retardation are described in
Table 3, splitting the sample in two according to the median
value of the RDS (which was 27). Patients with more severe
psychomotor retardation at baseline were signiﬁcantly more
frequently single, divorced or widowed (OR=1.29), having
an educational level below high school (OR=1.40) and not
presently working (OR=1.49). Furthermore, these patients
had higher QIDS-SR, SDS and CGI-S scores and had worst
performance in all cognitive tests (Table 3).
In testing which factors could inﬂuence the results of the
neurocognitive tests, we found that (i) age and (ii) presence
of a professional activity were involved in the speed at
which the TMT-A and TMT-B tests were performed (Table 4).
This was not the case, however, for educational level,
gender, marital status, and the hour at which the tests
were performed. Educational level was the only factor
inﬂuencing the three aspects of the d2 tests (GZ, BR, and
KL). The time at which the test was carried out alsoimpacted the KL value (concentration performance) on
the d2 test (Table 4).3.2. Follow-up values of the sample
Six to eight weeks later, a large improvement was observed
on all clinical and cognitive assessments (Table 2), with
67.68% of patients being responders and 43.31% of patients
being in remission (N=887). During the observational per-
iod, the dose of agomelatine was increased to 50 mg in
17.30% of patients, this group of patients being comparable
to the other patients in terms of gender, age, marital status,
educational level, and professional activity (p40.11), but
also in terms of baseline severity of depression (p40.33)
and psychomotor retardation according to clinical or cogni-
tive assessments (p40.10).
At the second visit, there were differences between
remitted patients and non-remitted patients regarding
several traits (described in Table 5). Apart from having—by
deﬁnition—less severe clinical symptoms and functional
difﬁculties, patients in remission after treatment were
younger, showed a tendency to have had fewer previous
depressive episodes, had a lower degree of psychomotor
retardation, were quicker on TMT-A and TMT-B, and quoted
Table 4 Inﬂuence of socio-demographic and clinical characteristics in two neurocognitive tests at baseline in a sample of
2048 depressed outpatients.
Characteristics TMT-A TMT-B d2 test
Speed Errors Speed Errors GZ BR KL
Age r 0.097 0.027 0.129 0.071 0.052 0.076 0.076
N 882 953 823 852 458 458 458
p 0.004 0.409 o0.001 0.038 0.265 0.103 0.265
Gender F 1.610 0.466 0.621 1.459 1.572 0.463 0.394
df 901 972 841 866 466 466 466
p 0.205 0.505 0.431 0.227 0.211 0.497 0.530
Professional activity F 7.724 0.741 6.555 2.613 1.354 1.265 0.663
df 653 703 613 628 346 346 346
p o0.001 0.477 0.002 0.074 0.260 0.284 0.516
Educational level F 0.799 0.013 1.537 2.113 10.060 13.222 10.758
df 876 945 819 844 455 455 455
p 0.372 0.908 0.215 0.146 0.002 o0.001 0.001
Marital status F 0.193 0.655 2.089 2.324 0.001 0.140 0.264
df 885 960 828 856 460 460 460
p 0.661 0.419 0.149 0.128 0.978 0.708 0.608
Time at which the test was done r 0.047 0.015 0.050 0.028 0.083 0.080 0.094
N 882 955 826 852 450 450 450
p 0.160 0.651 0.148 0.415 0.078 0.091 0.047
Length of the present episode r 0.034 0.023 0.018 0.038 0.029 0.078 0.077
N 895 967 835 862 466 466 466
p 0.306 0.483 0.597 0.260 0.092 0.092 0.099
Number of episodes r 0.094 0.009 0.137 0.085 0.133 -0.132 0.123
N 896 965 836 861 464 464 464
p 0.005 0.775 o0.001 0.013 0.004 0.004 0.008
1635Psychomotor retardation is a scar of past depressive episodes, revealed by simple cognitive testsmore correct items and less incorrect items in the d2 test
(Table 5).
Some patients (N=876; 42.77%) were declared by the
clinician as having received some form of psychotherapy
during the study period. This group of patients was compar-
able in terms of gender, age, marital status, and profes-
sional activity (p40.11) and had equivalent levels of
baseline severity according to the QIDS and CGI scale
(p40.22) compared with the rest of the sample. Patients
who received psychotherapy nevertheless had higher base-
line levels of psychomotor retardation according to the RDS
(po0.001) and the time needed to carry out the TMT-A
(6.89 more seconds; p=0.026) and TMT-B (10.45 more
seconds; p=0.016), with the average number of past
depressive episodes also being higher in this group (1.00
compared with 0.84; p=0.019).3.3. The impact of past depressive episodes on
retardation
At baseline, the number of past depressive episodes corre-
lated with both the clinical (CGI, QIDS, and RDS) assess-
ments of depression and the neurocognitive tests (speed of
the TMT and d2 variables) (Table 6). However, when con-
trolling for age, educational level, and professional activity,
only the clinical assessments (po0.04) and the speed at
which the TMT tests were carried out (po0.003) signiﬁ-
cantly correlated with the number of past episodes.We performed these analyses a second time, focusing on
the second set of assessments for the whole group of
patients (Table 6). For the neurocognitive tests, the pre-
vious analyses were conﬁrmed, showing that the speed on
both the TMT and d2 tests is indeed correlated with the
number of past depressive episodes (Table 6, Figure 1). But
when covariates were included in the analyses, KL and BR
values were no longer signiﬁcantly involved.
We then focused on patients in clinical remission at the
second visit, and found no clinical or social features that
continued to reﬂect the number of past episodes; however,
the speed on the TMT-A and TMT-B tests and the GZ
(quantitative performance) value did continue to reﬂect
this, even when controlling for the three covariates
(Table 6).4. Discussion
In testing whether psychomotor retardation—as assessed by the
clinician and through neurocognitive tests—could be a marker
of the cumulative burden of past depressive episodes, we found
that the speed at which TMT-A and TMT-B were performed was
the only assessment that fulﬁlled the requirements that we set
out to test. This was in a relatively large sample of depressed
outpatients, before and after treatment. Indeed, the speed at
which the TMT tests were carried out correlated with the
number of past depressive episodes at baseline, but also after
treatment, even when restricting the analyses to patients in
Table 5 Clinical and cognitive characteristics of 2048 outpatients after 6 to 8 weeks of antidepressant treatment, according
to the presence (versus the absence) of remission.
Characteristics Subgroups In remission
(N=885)
Not in remission
(N=1161)
Statistics
Average
or %
SD Average or
%
SD t or
χ2
df p
Gender Female 61.13% 64.68% 2.72 1 0.100
Male 38.87% 35.32%
Age 44.72 12.23 45.88 12.29 2.08 1989 0.019
Marital status Living with a partner 47.17% 46.73% 0.04 1 0.844
Alone 52.83% 53.27%
Highest educational level Below high school 56.53% 54.42% 0.87 1 0.350
Over high school 43.47% 45.58%
Professional activity
(presently)
Yes 43.13% 45.58% 0.06 1 0.811
No 56.53% 54.42%
Length of present episode
(weeks)
10.60 36.78 9.36 12.50 0.86 1621 0.196
Number of past episodes 1.45 8.44 1.99 9.33 1.30 1854 0.097
QIDS-SR total score 2.90 1.65 10.33 4.15 55.52 2046 o103
DSM-IV criteria 6.95 1.10 7.16 1.08 4.19 2046 o103
CGI-S score 1.82 0.92 3.37 1.20 33.06 2046 o103
RDS score 5.61 4.79 16.13 8.06 34.42 2009 o103
SDS score Work/studies 1.93 1.64 4.58 2.01 27.78 1469 o103
Social life 1.86 1.64 4.88 2.16 35.55 2006 o103
Family 1.74 1.60 4.72 2.16 35.49 2006 o103
TMT-A neurocognitive test Time (seconds) 36.77 32.21 43.42 40.09 2.83 944 0.002
Mistakes (number) 0.40 4.47 0.46 1.68 0.27 1009 0.391
TMT-B neurocognitive test Time (seconds) 58.03 48.21 73.66 65.83 4.12 909 o103
Mistakes (number) 0.95 6.14 1.16 3.24 0.63 938 0.266
d2 neurocognitive test GZ (number of marked items) 393.26 166.60 371.24 167.81 1.37 437 0.085
BR (number of correct marked
items)
146.98 69.02 136.01 69.60 1.65 437 0.049
Kl (correct–incorrect marked
items)
140.61 70.41 126.52 71.51 2.07 437 0.019
CGI-S, Clinical Global Impression Severity; QIDS-SR, Self-Report Quick Inventory of Depressive Symptomatology; RDS, Retardation
Depressive Scale; SDS, Sheehan Disability Scale; TMT, Trail Making Test.
P. Gorwood et al.1636remission. Furthermore, even though certain confounders were
detected that partly explained the speed at which the TMTwas
performed, controlling for these did not reduce the strength of
the observed correlation.
If such results are conﬁrmed in an independent sample,
and especially if neurocognitive assessments are performed
at a greater distance from remission, the present ﬁnding
could be considered an important step towards understand-
ing why and how, with more past depressive episodes, there
exists a higher degree of remaining symptoms (Judd, 2012),
poorer functional remission (Sarapas et al., 2013) and
higher risk of later relapses (Solomon et al., 1997). It could
also shed light on the fact that patients with residual
depressive symptoms have an increased risk of relapse
compared to those patients in full remission (Cornwall and
Scott, 1997; Paykel et al., 1995), as residual depressive
symptoms might also reﬂect psychomotor retardation.
The results of our study also stress for the ﬁrst time that
distinguishing between the neurocognitive and clinicalaspects of psychomotor retardation is fruitful, potentially
not only for research into the mechanisms involved in the
recurrence of major depressive disorder, but also for ensur-
ing more adequate treatment approaches for prevention
strategies.
In our study, TMT-A and TMT-B appeared to more directly
reveal the impact of past depressive episodes—whatever the
time point of the assessment—than the different aspects of
the d2 test. Furthermore, the simple TMT-A (drawing a line
between numbers increasing in value) performed equally
well as the more demanding TMT-B (which requires set
shifting). Accordingly, the value from the d2 test that
performed best was GZ (Table 6), which consists of the
number of total signs marked, even if they are not appro-
priate. These three results could plead in favor of a speciﬁc
role for speed, rather than accuracy and complexity, and
thus psychomotor retardation.
One potential explanation for this result is that the
aspects of psychomotor retardation involved in such scar
Table 6 Correlation between the number of past depressive episodes and demographic, clinical, and cognitive
characteristics of depressed outpatients, at baseline and after treatment (for all patients, and those in remission).
Variables At baseline (N=1856) After treatment
Whole sample (N=1856) Remitted patients (N=475)
F r p p' r p p' F r p p'
Age 0.244 o0.001 0.209 o0.001
Gender 0.311 0.577 2.612 0.107
Professional activity 0.247 0.117 2.564 0.078
Marital status 1.351 0.245 0.302 0.583
Educational level 21.211 o0.001 10.736 0.001
Psychomotor retardation
(RDS)
0.099 o0.0010 0.007 0.117 o0.0010 0.068 0.033 0.488 0.150
CGI-S 0.124 o0.001 0.0060 0.099 o0.001 0.068 0.011 0.816 0.186
QIDS-SR 0.0780 0.001 0.039 0.129 o0.001 0.007 0.012 0.788 0.526
SDS 0.048 0.093 0.086 0.099 o0.001 0.048 0.044 0.406 0.186
TMT-A (errors) 0.009 0.775 0.710 0.117 0.610 0.384 0.036 0.536 0.449
TMT-A (speed) 0.094 0.005 0.002 0.129 o0.001 0.002 0.292 o0.001 o0.001
TMT-B (errors) 0.085 0.013 0.905 0.112 0.722 0.321 0.039 0.512 0.505
TMT-B (speed) 0.137 0.004 0.001 0.166 o0.001 o0.001 0.214 o0.001 o0.001
GZ (d2 test) 0.133 0.004 0.125 0.200 o0.001 0.006 0.221 0.021 0.009
Kl (d2 test) 0.123 0.008 0.163 0.125 0.013 0.172 0.148 0.122 0.139
BR (d2 test) 0.132 0.004 0.136 0.141 0.005 0.158 0.157 0.103 0.087
p0: the p-Value controlling for ‘age’, ‘educational level’ and ‘professional activity’.
CGI-S, Clinical Global Impression Severity; QIDS-SR, Self-Report Quick Inventory of Depressive Symptomatology; RDS, Retardation
Depressive Scale; SDS, Sheehan Disability Scale; TMT, Trail Making Test.
1637Psychomotor retardation is a scar of past depressive episodes, revealed by simple cognitive testseffects, are: (i) above attention (which is a prerequisite to
test speed); (ii) below cognitive ﬂexibility or executive
dysfunction (which is more demanding, and potentially
more contaminated by depressive symptoms); and (iii)
different to the usual clinical assessments as captured by
the RDS (potentially because of the overlap with the
severity of the depressive episode). The nature of executive
dysfunction in depression has not been fully clariﬁed.
Although psychomotor slowing is well documented in mood
disorder (e.g., Austin et al., 2001), and is one of the
diagnostic criteria for the disorder, other cognitive impair-
ments in mood disorder include deﬁcits in attention control,
working memory, and processing speed (Elderkin-Thompson
et al., 2004). These information-processing deﬁcits can, in
turn, affect performance on other cognitive processes,
including executive function (for a general discussion, see
Robbins et al., 1998).
Cognitive speed might be more speciﬁcally involved, as a
previous study of depression and cognition in multiple
sclerosis concluded that the patients with depression were
mainly characterized by slow information processing speed,
whereas executive functioning was unaffected (Arnett
et al., 1994). In younger patients with moderate depression,
no impairment was reported in working memory whereas a
signiﬁcant decrease in motor speed and attention set-
shifting (Purcell et al., 1997) was observed, with those with
overall greater illness severity (higher rate of admission for
treatment of depression) being more impaired on the set-
shifting task. In searching for a relevant phenotype in mood
disorder, one study detected that patients with the highestscore on psychomotor retardation testing were also the ones
with a longer duration of illness, an earlier age of onset, and
more depressive episodes, which is clearly in accordance
with our own results (Calugi et al., 2011). Interestingly,
psychomotor retardation was a predictor of delayed
response to treatment with either interpersonal psychother-
apy or selective serotonin reuptake inhibitor pharmacother-
apy (Frank et al., 2011).
Psychomotor retardation might, therefore, capture the
negative impact of past depressive episodes in accordance with
Widlocher's description (1983). Widlocher proposed that psy-
chomotor retardation (including both observed motor behavior
and inferred mental functions) is a ‘primary disturbance’ in
affective disorders. Aside from the present study, this view is
also supported by positive research showing stable cognitive
abnormalities after remission (Paradiso et al., 1997; Kessing,
1998), and a correlation between lifetime depression and: (i) a
composite score of cognitive impairment (Kessing, 1998;
Hasselbalch et al., 2013); (ii) response latencies using compu-
terized tests such as CANTAB (Beats et al., 1996); (iii) executive
functions requiring planning and problem solving (Bhardwaj
et al., 2010); (iv) longer time to perform tests requiring
attention and executive functions (Paelecke-Habermann
et al., 2005); and even (v) TMT-A and TMT-B performance
(relying on number of hospitalizations rather than on number of
depressive episodes) (Preiss et al., 2009). Psychomotor retarda-
tion has also been assessed on a more clinical basis through the
use of a lifetime psychomotor retardation (LPR) factor, which
showed that compared with patients with low scores, high LPR
scorers had more past depressive episodes (Calugi et al., 2011).
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Figure 1 TMT-A performance (speed) according to the number
of past depressive episodes.
The time needed to perform Trail Making Test A (TMT-A)
increases with the number of past depressive episodes, both
when carried out at baseline (blue boxes) and when carried out
after treatment on the whole sample (red boxes) and when
limited to patients in remission (green boxes). See Table 4 for
corresponding correlations. (For interpretation of the refer-
ences to color in this ﬁgure legend, the reader is referred to the
web version of this article.)
P. Gorwood et al.1638Also, interestingly, in a sample of 25 bipolar patients who were
euthymic for 3 months, the result of the TMT-B test correlated
with the cumulative duration of past depressive episodes, but
not of manic episodes (Van Gorp et al., 1998). Cognitive
impairment in MDD has been associated with higher rates of
relapse and recurrence (Majer et al., 2004; Sumner et al.,
2010), reinforcing the idea that neurocognitive abnormalities
could constitute markers of acquired vulnerability. Neverthe-
less, not all studies have conﬁrmed the hypothesis of a direct
link between past depressive episodes and cognitive abnormal-
ities (for review see Hasselbalch et al., 2013). This is in fact to
be expected if one considers the weight of past episodes on
neurocognitive abnormalities, which is regularly quoted in these
studies as being of medium to small range, and thus requires
large samples to be detected. Indeed, these negative studies
have had more limited statistical power, as the number of
patients has been below 30. Another source of heterogeneity in
the results arises from the fact that the studies have investi-
gated various aspects of neurocognitive deﬁcits that might not
systematically overlap.Different limitations in our work should be pointed out.
First, not all patients received the neurocognitive tests,
therefore it is expected that bias would have occurred in
those patients who were recruited with higher levels of
cooperativeness and who were potentially less depressed.
However, the clinical characteristics of the patients who
carried out the tests were largely comparable with the rest
of the sample (see Section 2). Another limitation of our
sample is the requirement of no associated medication,
antipsychotic, mood stabilizer, or benzodiazepine. Although
this was needed to obtain valid neurocognitive test results,
it is possible that severely depressed anxious patients
needing co-prescription were less frequently recruited in
this non-interventional study. On the other hand, the
sample tested in this study had a large degree of variability
in terms of severity and past number of episodes, which
were the only prerequisites for inclusion. In line with this,
the SD of the delay between the two visits was relatively
large (SD=11). In accordance with the fact that this was a
non-interventional study, we proposed a relatively large
time lag before the second visit to facilitate inclusion. This
potential issue may in fact have had limited impact, as the
lag was not associated with any clinical or cognitive
characteristics of patients at the second visit.
Another potential limitation is that, although we assessed
three aspects of psychomotor retardation through neuro-
cognitive tests and a speciﬁc clinical assessment, it is
difﬁcult to predict if our results would be replicated if
relying on other important aspects of psychomotor retarda-
tion, more clearly distinguishing motor from cognitive
aspects of neurocognitive retardation, such as the ones
related to movement and speech. Examples would be speed
and paucity of movement and walk, objective latencies,
pauses, lack of reactivity, difﬁculty of initiation, and speed
of speech. The third limitation relates to the fact that all
patients in the study received treatment, and with a single
drug, with neither placebo nor comparator. With no com-
parator, it is difﬁcult to detect if the cognitive improvement
with agomelatine is a speciﬁc effect, and with no placebo,
it is difﬁcult to know if the same results at remission would
be found with no antidepressive treatment.
The presence of another axis I DSM-IV diagnosis and non-
antidepressant psychotropic treatments constituted exclu-
sion criteria. It is nevertheless difﬁcult to rule out the
presence of comorbidity in our sample (such as bipolar
disorder or generalized anxiety disorders), especially as no
structured interview was performed at baseline. This pro-
blem could have consequences. For example, bipolar dis-
order patients with a mixed depression have lower
retardation level according to one study (Sani et al.,
2014) and a signiﬁcant correlation (r40.4) has been
detected between anxiety and psychomotor retardation in
depressed patients (Goekoop et al., 2006). It is therefore
important to state that, even if our ﬁndings were detected
in depressed patients, speciﬁcally attributing our results to
non-comorbid major depressive disorder would require a
structured interview encompassing potentially associated
bipolar and anxiety disorders.
Last, a practice effect is always difﬁcult to control for
when performing neurocognitive tests at least twice, and
may partly explain the improvement observed at the second
visit. Indirect evidence might plead against a major role for
1639Psychomotor retardation is a scar of past depressive episodes, revealed by simple cognitive teststhis bias, as in restricting the analyses to all (N=14)
patients who had exactly the same QIDS value at the two
visits (and were therefore not inﬂuenced by the expected
decrease in depressive symptoms), we did not ﬁnd a
signiﬁcant improvement. Taken together, these results
might plead in favor of a scar effect of past depressive
episodes, although long-term studies conducted at a dis-
tance from any depressive episode would be the most
adequate way to reach any conclusion.
If it can be prospectively conﬁrmed that past depressive
episodes have a negative cumulative impact on psychomo-
tor retardation, intervention might be proposed for at-risk
individuals, mainly in the early stages of depressive dis-
order. First-episode disorders might indeed be more sensi-
tive to care, especially as psychotherapy early in life and at
early stages of illness might reduce the rate of recurrence of
depressive episodes (Clarke et al., 1999; Jarrett et al.,
2001) and as the development of psychotropic drugs now
involves neurocognition (Millan et al., 2012).
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